Radiotherapist’s View on the Role of Current Diagnostic Imaging in Pre-Radiation Preparation of Patients with Oligometastatic Disease for Conformal Radiotherapy
https://doi.org/10.20862/0042-4676-2024-105-2-107-113
Abstract
Diagnostic imaging of oligometastatic disease is a difficult task, since it requires determining the exact locoregional stage of the underlying disease and assessing the condition of the entire body in terms of possible diffuse spread of distant metastases, which presupposes a fairly frequent combination of various instrumental methods. In each specific case, a more accurate imaging method is chosen depending on the type of tumor, time of diagnosis, possible previously implemented stage of special antitumor treatment, as well as the individual risk of developing distant metastases, the most characteristic for this type of tumor process. Today, along with some diagnostic techniques that were previously constantly used in everyday practice, but are gradually losing their long-standing clinical application, such imaging methods as contrastenhanced computed tomography (CT), magnetic resonance imaging, as well as metabolic and specific receptor imaging, for example, CT combined with positron emission tomography with 18F-fluorodeoxyglucose, are most commonly performed, alone or in various combinations.
About the Authors
G. A. Panshin
Russian Scientific Center of Roentgenoradiology
Russian Federation
Russian Federation
Georgiy А. Panshin, Dr. Med. Sc., Professor, Senior Resеаrcher, Laboratory of Radiation Therapy and Complex Methods of Cancer Treatment, Research Department of Complex Diagnostics of Diseases and Radiotherapy
ul. Profsoyuznaya, 86, Moscow, 117997
N. V. Nudnov
Russian Scientific Center of Roentgenoradiology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Nikolay V. Nudnov, Dr. Med. Sc., Professor, Deputy Director for Scientific Work, Head of Research Department of Complex Diagnostics of Diseases and Radiotherapy; Professor, Chair of Radiology and Nuclear Medicine
ul. Profsoyuznaya, 86, Moscow, 117997
ul. Barrikadnaya, 2/1, str.1, Moscow, 125993
References
1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10. https://doi.org/10.1200/JCO.1995.13.1.8.
2. Panshin GA. Oligometastatic disease and remote stereotactic ablative radiotherapy of the body (general issues). Vestnik of the Russian Scientific Center of Roentgenoradiology. 2023; 23(3): 32–43 (in Russ).]
3. D’Onofrio M, Crosara S, De Robertis R. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015; 205(1): W56–66. https://doi.org/10.2214/AJR.14.14203.
4. O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol. 2015; 7(8): 202–11. https://doi.org/10.4329/wjr.v7.i8.202.
5. Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstet Invest. 2017; 82(3): 209–22. https://doi.org/10.1159/000456006.
6. deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer. 2019; 144(3): 422–30. https://doi.org/10.1002/ijc.31793.
7. Lo SS, Gore EM, Bradley JD, et al. ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases. J Palliat Med. 2014; 17(8): 880–6. https://doi.org/10.1089/jpm.2014.9417.
8. Barzilai O, Laufer I, Yamada Y, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanicals stability, and systemic disease. J Clin Oncol. 2017; 35(21): 2419–27. https://doi.org/10.1200/JCO.2017.72.7362.
9. Mizukami Y, Ueda S, Mizumoto A, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011; 35(4): 895–9. https://doi.org/10.1007/s00268-011-0986-x.
10. Lecouvet FE. Whole-body MR imaging: musculoskeletal applications. Radiology. 2016; 279(2): 345–65. https://doi.org/10.1148/radiol.2016142084.
11. Jouvet JC, Thomas L, Thomson V, et al. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PETCT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol. 2014; 28(2): 176–85. https://doi.org/10.1111/jdv.12078.
12. Perez-Lopez R, Lorente D, Blackledge MD, et al. Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer. Radiology. 2016; 280(1): 151–60. https://doi.org/10.1148/radiol.2015150799.
13. Chong A, Hwang I, Ha JM, et al. Application of bone scans for prostate cancer staging: which guideline shows better result? Can Urol Assoc J. 2014; 8(7–8): E515–9. https://doi.org/10.5489/cuaj.2054.
14. Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016; 43(9): 1723–38. https://doi.org/10.1007/s00259-016-3415-4.
15. Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012; 12: 305. https://doi.org/10.1186/1471-2407-12-305.
16. Olson R, Liu M, Bergman A, et al. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer. 2018; 18(1): 954. https://doi.org/10.1186/s12885-018-4859-7.
17. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABRCOMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19(1): 816. https://doi.org/10.1186/s12885-019-5977-6.
18. Olson R, Jiang W, Liu M, et al. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol. 2022; 8(11): 1644–50. https://doi.org/10.1001/jamaoncol.2022.4394.
19. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148: 157–66. https://doi.org/10.1016/j.radonc.2020.04.003.
20. Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022; 14(14): 3302. https://doi.org/10.3390/cancers14143302.
21. Artigas C, Diamand R, Shagera QA, et al. Oligometastatic disease detection with 68Ga-PSMA-11 PET/CT in hormonesensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical impact. Cancers (Basel). 2021; 13(19): 4982. https://doi.org/10.3390/cancers13194982.
22. Christ SM, Pohl K, Willmann J, et al. Patterns of metastatic spread and tumor burden in unselected cancer patients using PET imaging: implications for the oligometastatic spectrum theory. Clin Transl Radiat Oncol. 2024; 45: 100724. https://doi.org/10.1016/j.ctro.2024.100724.
23. Christ SM, Pohl K, Muehlematter UJ, et al. Imaging-based prevalence of oligometastatic disease: a single-center crosssectional study. Int J Radiat Oncol Biol Phys. 2022; 114(4): 596–602. https://doi.org/10.1016/j.ijrobp.2022.06.100.
24. McCarthy M, Francis R, Tang C, et al. A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: oligometastatic rate and distribution compared with standard imaging. Int J Radiat Oncol Biol Phys. 2019; 104(4): 801–8. https://doi.org/10.1016/j.ijrobp.2019.03.014.
25. Romero A, Serna-Blasco R, Calvo V, Provencio M. Use of liquid biopsy in the care of patients with non-small cell lung cancer. Curr Treat Options Oncol. 2021; 22(10): 86. https://doi.org/10.1007/s11864-021-00882-9.
26. Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012; 18(20): 5701–10. https://doi.org/10.1158/1078-0432.CCR-12-1587.
27. Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020; 1(3): 276–90. https://doi.org/10.1038/s43018-020-0043-5.
Review
For citations:
Panshin G.A., Nudnov N.V. Radiotherapist’s View on the Role of Current Diagnostic Imaging in Pre-Radiation Preparation of Patients with Oligometastatic Disease for Conformal Radiotherapy. Journal of radiology and nuclear medicine. 2024;105(2):107-113. (In Russ.) https://doi.org/10.20862/0042-4676-2024-105-2-107-113
Views:
128
Email this article 